From the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University.
Veterans Administration Medical Center, Atlanta, Georgia.
Clin Nucl Med. 2019 Nov;44(11):e614-e616. doi: 10.1097/RLU.0000000000002670.
Since its recent approval by the United States Food and Drug Administration, fluciclovine PET-CT has gained widespread use for imaging of recurrent prostate cancer patients. As an amino acid-based radiotracer transported by LAT-1 and ASCT-2 transporters, fluciclovine exploits the up-regulation of amino acid transporters in malignant cells. We present a rare case of fluciclovine uptake in Paget disease in a 58-year-old man with suspected recurrent prostate cancer and asymmetric increased left hemipelvic uptake on imaging.
氟尿苷 PET-CT 最近获得美国食品和药物管理局批准，已广泛用于复发性前列腺癌患者的成像。作为一种由 LAT-1 和 ASCT-2 转运体转运的氨基酸放射性示踪剂，氟尿苷利用恶性细胞中氨基酸转运体的上调。我们报告了一例罕见的氟尿苷摄取病例，发生在一名 58 岁男性中，该患者有疑似复发性前列腺癌，影像学表现为左侧半骨盆不对称性摄取增加。
